Saud H Aldubayan, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Germ-Line Mutation | 11 | 2022 | 1788 | 1.250 |
Why?
|
Genetic Testing | 6 | 2021 | 3444 | 1.050 |
Why?
|
Testicular Neoplasms | 3 | 2021 | 804 | 0.940 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 501 | 0.720 |
Why?
|
Prostatic Neoplasms | 10 | 2021 | 11124 | 0.700 |
Why?
|
Propionic Acidemia | 1 | 2017 | 9 | 0.600 |
Why?
|
Arabs | 3 | 2023 | 178 | 0.540 |
Why?
|
Carnitine | 1 | 2017 | 246 | 0.540 |
Why?
|
Inheritance Patterns | 1 | 2018 | 340 | 0.530 |
Why?
|
Genetic Predisposition to Disease | 12 | 2022 | 17446 | 0.510 |
Why?
|
Metabolism, Inborn Errors | 1 | 2017 | 288 | 0.500 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2017 | 255 | 0.490 |
Why?
|
DNA Repair | 4 | 2020 | 2046 | 0.440 |
Why?
|
DNA Mutational Analysis | 2 | 2020 | 4186 | 0.430 |
Why?
|
DNA Mismatch Repair | 3 | 2019 | 426 | 0.370 |
Why?
|
Germ Cells | 4 | 2022 | 631 | 0.350 |
Why?
|
Fatty Acids | 1 | 2017 | 1809 | 0.330 |
Why?
|
Breast Neoplasms | 2 | 2023 | 20822 | 0.270 |
Why?
|
Melanoma | 2 | 2020 | 5510 | 0.260 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2023 | 106 | 0.220 |
Why?
|
Colorectal Neoplasms | 2 | 2019 | 6773 | 0.200 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2021 | 114 | 0.190 |
Why?
|
DNA Repair-Deficiency Disorders | 1 | 2020 | 29 | 0.190 |
Why?
|
Disease Management | 4 | 2018 | 2459 | 0.170 |
Why?
|
Peroxisomal Disorders | 1 | 2018 | 12 | 0.170 |
Why?
|
Neurofibromin 1 | 1 | 2020 | 196 | 0.170 |
Why?
|
Tamoxifen | 1 | 2023 | 981 | 0.160 |
Why?
|
Acute Disease | 3 | 2018 | 7149 | 0.160 |
Why?
|
Repressor Proteins | 2 | 2021 | 3023 | 0.160 |
Why?
|
Urea Cycle Disorders, Inborn | 1 | 2018 | 31 | 0.160 |
Why?
|
Maple Syrup Urine Disease | 1 | 2018 | 39 | 0.160 |
Why?
|
Microsatellite Instability | 2 | 2018 | 684 | 0.150 |
Why?
|
Pathology, Molecular | 1 | 2021 | 326 | 0.150 |
Why?
|
Genetic Counseling | 1 | 2021 | 600 | 0.150 |
Why?
|
GTP Phosphohydrolases | 1 | 2020 | 509 | 0.150 |
Why?
|
Multigene Family | 1 | 2019 | 1102 | 0.140 |
Why?
|
Genes, Neoplasm | 1 | 2018 | 376 | 0.140 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2021 | 5172 | 0.130 |
Why?
|
Humans | 32 | 2023 | 744343 | 0.130 |
Why?
|
Anemia, Sickle Cell | 1 | 2022 | 1018 | 0.120 |
Why?
|
Breast | 1 | 2023 | 1969 | 0.120 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1038 | 0.120 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2020 | 3597 | 0.110 |
Why?
|
Male | 18 | 2021 | 350118 | 0.110 |
Why?
|
Genomics | 4 | 2023 | 5720 | 0.110 |
Why?
|
Androgen Antagonists | 1 | 2021 | 1377 | 0.110 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2014 | 314 | 0.110 |
Why?
|
Mutation | 8 | 2023 | 29786 | 0.110 |
Why?
|
Marfan Syndrome | 1 | 2014 | 240 | 0.100 |
Why?
|
Early Diagnosis | 1 | 2017 | 1184 | 0.100 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2016 | 379 | 0.100 |
Why?
|
Prostate-Specific Antigen | 1 | 2021 | 2494 | 0.100 |
Why?
|
Oxidation-Reduction | 1 | 2017 | 2187 | 0.100 |
Why?
|
Emergency Medicine | 2 | 2018 | 1207 | 0.100 |
Why?
|
Hematopoiesis | 1 | 2020 | 2072 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2020 | 2043 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1897 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2021 | 2948 | 0.090 |
Why?
|
Aortic Aneurysm | 1 | 2014 | 643 | 0.080 |
Why?
|
Microfilament Proteins | 1 | 2014 | 1152 | 0.080 |
Why?
|
Carcinoma | 1 | 2019 | 2375 | 0.080 |
Why?
|
Disease Progression | 2 | 2021 | 13284 | 0.070 |
Why?
|
Nuclear Proteins | 1 | 2021 | 5853 | 0.070 |
Why?
|
MicroRNAs | 1 | 2022 | 3752 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4838 | 0.070 |
Why?
|
Actins | 1 | 2014 | 2121 | 0.070 |
Why?
|
Genotype | 1 | 2021 | 12951 | 0.070 |
Why?
|
Female | 9 | 2023 | 380194 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3703 | 0.070 |
Why?
|
Risk Factors | 3 | 2023 | 72290 | 0.070 |
Why?
|
Critical Care | 1 | 2018 | 2647 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14722 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 15076 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2020 | 7880 | 0.060 |
Why?
|
Genome, Human | 1 | 2016 | 4420 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 11524 | 0.050 |
Why?
|
Immunotherapy | 1 | 2018 | 4445 | 0.050 |
Why?
|
Middle Aged | 8 | 2021 | 213383 | 0.050 |
Why?
|
Glycosphingolipids | 1 | 2022 | 79 | 0.050 |
Why?
|
Hemoglobin, Sickle | 1 | 2022 | 122 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2020 | 5181 | 0.050 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2020 | 5442 | 0.050 |
Why?
|
Saudi Arabia | 1 | 2022 | 209 | 0.050 |
Why?
|
beta-Globins | 1 | 2022 | 113 | 0.050 |
Why?
|
gamma-Globins | 1 | 2022 | 95 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8428 | 0.050 |
Why?
|
Neoplasms | 2 | 2021 | 21683 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2020 | 5686 | 0.050 |
Why?
|
Adult | 7 | 2021 | 214055 | 0.050 |
Why?
|
Case-Control Studies | 1 | 2019 | 21746 | 0.050 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2021 | 250 | 0.050 |
Why?
|
Fetal Hemoglobin | 1 | 2022 | 341 | 0.040 |
Why?
|
Young Adult | 4 | 2020 | 56430 | 0.040 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2021 | 315 | 0.040 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 25043 | 0.040 |
Why?
|
Genetic Variation | 1 | 2014 | 6544 | 0.040 |
Why?
|
Cohort Studies | 2 | 2018 | 40561 | 0.040 |
Why?
|
Dioxygenases | 1 | 2020 | 316 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 2 | 2021 | 4554 | 0.040 |
Why?
|
Facies | 1 | 2018 | 197 | 0.040 |
Why?
|
Consanguinity | 1 | 2018 | 454 | 0.040 |
Why?
|
Aged | 6 | 2020 | 163280 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2016 | 4851 | 0.030 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2016 | 223 | 0.030 |
Why?
|
MutS Homolog 2 Protein | 1 | 2016 | 200 | 0.030 |
Why?
|
Ontario | 1 | 2016 | 383 | 0.030 |
Why?
|
Receptors, Androgen | 1 | 2021 | 1058 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2020 | 2124 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 684 | 0.030 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2020 | 986 | 0.030 |
Why?
|
Teratoma | 1 | 2016 | 395 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2022 | 2503 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2022 | 2109 | 0.030 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2021 | 1524 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 890 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2938 | 0.030 |
Why?
|
Prostatectomy | 1 | 2021 | 1890 | 0.030 |
Why?
|
Multifactorial Inheritance | 1 | 2020 | 1194 | 0.030 |
Why?
|
History, 20th Century | 1 | 2020 | 2740 | 0.030 |
Why?
|
DNA Damage | 1 | 2022 | 2432 | 0.030 |
Why?
|
Phenotype | 2 | 2020 | 16365 | 0.030 |
Why?
|
Leukocytes | 1 | 2020 | 2043 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1782 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1142 | 0.020 |
Why?
|
Family Health | 1 | 2016 | 1282 | 0.020 |
Why?
|
Pedigree | 1 | 2018 | 4644 | 0.020 |
Why?
|
DNA-Binding Proteins | 2 | 2020 | 9648 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2019 | 1941 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2728 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2018 | 1738 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 3462 | 0.020 |
Why?
|
Phylogeny | 1 | 2016 | 2803 | 0.020 |
Why?
|
Heterozygote | 1 | 2016 | 2804 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2018 | 2703 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1692 | 0.020 |
Why?
|
Risk | 1 | 2021 | 9687 | 0.020 |
Why?
|
Cost of Illness | 1 | 2018 | 1859 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2019 | 2183 | 0.020 |
Why?
|
Population Surveillance | 1 | 2018 | 2616 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2020 | 2133 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1940 | 0.020 |
Why?
|
Program Evaluation | 1 | 2016 | 2488 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2020 | 7722 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11366 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2018 | 3528 | 0.020 |
Why?
|
DNA Methylation | 1 | 2019 | 4286 | 0.020 |
Why?
|
Mitochondria | 1 | 2016 | 3520 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2020 | 57776 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 19905 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9438 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2021 | 77449 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15226 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 4803 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7279 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12261 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 16689 | 0.010 |
Why?
|
Child | 2 | 2022 | 77709 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2020 | 15519 | 0.010 |
Why?
|
Apoptosis | 1 | 2016 | 9727 | 0.010 |
Why?
|
Physicians | 1 | 2018 | 4567 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18370 | 0.010 |
Why?
|
Prognosis | 1 | 2018 | 29063 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 20947 | 0.010 |
Why?
|
Signal Transduction | 1 | 2020 | 23403 | 0.010 |
Why?
|
Algorithms | 1 | 2018 | 13881 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 53288 | 0.010 |
Why?
|
Adolescent | 2 | 2016 | 85781 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20129 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2014 | 25625 | 0.010 |
Why?
|
Infant | 1 | 2014 | 35136 | 0.010 |
Why?
|
Brain | 1 | 2018 | 26385 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 35421 | 0.010 |
Why?
|
Child, Preschool | 1 | 2014 | 41006 | 0.010 |
Why?
|
Mice | 1 | 2017 | 81183 | 0.010 |
Why?
|
Animals | 1 | 2017 | 168757 | 0.000 |
Why?
|